As part of CLL Global Research Foundation’s virtual town hall, Dr. Jackie Broadway-Duren responded to an audience question about the watch and wait period – emphasizing that every patient is different and making regular monitoring and ongoing conversations between patients and their care teams essential to determining the right time to start treatment.
Expert Panel:

Dr. Jackie Broadway-Duren, The University of Texas MD Anderson Cancer Center
Transcript:
I know it’s different for a lot of people. But how do you do that matrix? How do you work through that flow chart?
Dr. Jackie Broadway-Duren: Well, one of the main considerations is people want to make everything very technical. But sometimes just a plain, thorough physical examination can give you an idea that therapy may be ready. Meaning that you may have large lymph nodes in several places that are greater that 5 cm. Or maybe you’re having drenching night sweats or fatigue to where rest is required by late morning. But more technically, you want to look at those lab tests. You want to look at the CBC. It’s not based on just a white blood cell count. You also have to consider, does this patient, do they have favorable prognostic tests?
If we have a patient who doesn’t, they’re unmutated, which is considered unfavorable, they have a 17P or TP53 or 11q. So, all those things are taken into consideration. There have been times that patients may need to start therapy and they may only have 28,000 white cells versus someone that may have 128,000 and not need therapy yet because there’s nothing that’s causing that white count to double. It’s the doubling time of the white count. If it’s less than six months, then that is an indication for treatment.
If the patient’s overall well-being is deteriorating or if the platelets are dropping and the hemoglobin is dropping, all those things may be indication that it’s time to start therapy. So, there’s no one specific thing. You just combine all these pieces of the puzzle and then try and determine if, in fact, that patient is a candidate to initiate therapy now.
But I think one of the things that we do well in our leukemia department is we monitor the patients closely and try to help guide them to accept the fact that you’re likely going to need treatment but maybe not this month. But we’ll have them back in six months. So, you’ve then prepared the patient so that they themselves start looking at all these different aspects. That also can help the clinician make a determination. It’s the white count. It’s the prognostic test. It’s the symptomatology that the patient has. All those things are indicated.
Jeff Folloder: So, that’s a better way of saying it depends.
Dr. Jackie Broadway-Duren: It depends. It definitely depends on the patient.
Jeff Folloder: But it does make sense because every patient’s journey is different.
And I remember specifically when you and I were discussing this, it was a matter of not just the symptoms but how do you feel.
Dr. Jackie Broadway-Duren: Exactly.